Of the 494 patients, 43.5 percent received an injectable DMT, 17.4 percent dimethyl fumarate, 3.4 percent fingolimod, 10.1 percent natalizumab, 24.3 percent rituximab, and 1.2 percent other DMT. The researchers found that there were pronounced regional preferences, with 81 and 18 percent of patients...